Mike Hollan

The Phenomix CEO discusses recent data that suggests that patients may not be prepared for the side effects and unexpected costs of GLP-1s.

In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.

Phenomix CEO Mark Bagnall discusses the effectiveness of GLP-1s and how obesity impacts different patients in a variety of complex ways.

Phenomix CEO Mark Bagnall explains how GLP-1 users often face significant costs to deal with the side effects of GLP-1 usage.

GLP-1 side effects can be serious, and Phenomix CEO Mark Bagnall discusses the impact they can have on patients, who are not always fully educated.

Imunon’s CEO discusses how FDA allowing the Bayesian method impacts innovation in the clinical trial space.

Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why it’s common for patients to stop taking the medication.

Members of PacBio and iHope discuss collaboration and the global state of genomic testing.

Pharmaceutical companies that made MFN deals with the Trump administration will be exempt from the tariffs, along with other exemptions.

ADVI’s head of market access policy strategy discusses how the Trump administration’s efforts.

Soley Therapeutics’ CEO and co-founder discusses the importance of understanding why some cells survive under stress and others don’t.

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.

Yerem Yeghiazarians, MD, explains how understanding how various cells react differently to stress impacts how damaged cells may potentially be treated.

Drug pricing restrictions are likely to impact drug launches, especially for medications expected to be sought after by Medicare patients.

As opposed to starting with a target disease, Yerem Yeghiazarians, MD discusses how Soley instead focused on developing a method of identifying broad compounds.

While they may be linked, the administration’s DTC drug coupon site is not necessarily the entirety of its MFN efforts.

Yerem Yeghiazarians, MD, discusses the importance of understanding why certain cells (like cancer cells) can survive in situations that would kill other healthy cells.

For pharma products, ensuring proper delivery requires the majority of work to occur before the product hits the road.

eHealth’s vice president of consumer enablement discusses pricing and cost issues with GLP-1s.

While the space has traditionally been dominated by smaller biotechs, that may be changing.

Inclusive Capital Partners sold a stake worth about 0.9 % of the company.

Making changes in the pharma industry in operations is a slightly more expensive process because of larger compliances and regulatory pieces involved.

FDA has provided opportunities for R&D in rare disease, although recent developments have caused significant setbacks to occur.

Pharma products face unique issues related to chain-of-custody and cold chain.

In the final part of his conversation with Pharmaceutical Executive, Aravo CCO Dave Rusher discusses the various regulatory updates around the world in the pharma and AI space.

Limited patient populations require sponsors to adapt their practices when working in the rare disease space.

While digital clinical trials provide more opportunity, they also present unique challenges that can significantly impact the trial results.

The ruling places a hold on any decisions made by the council, although the government does plan to appeal the ruling.

Dave Rusher, CCO at Aravo, explains the relationship between large, publicly available LLMs and how private LLMs might benefit the pharma industry.

Jiang Li, CEO of Vivalink, continues his conversation with Pharmaceutical Executive, this time discussing the impact of continuous monitoring on patient adherence.